Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective

References

• Hogerzeil H, Access to essential medicines as a human right. World Health Organisation. Essent Drugs Monit. 2003;33:25–26. Available from: http://apps.who.int/medicinedocs/en/d/Js4941e/5.html Accessed July 3, 2019.
   Google Scholar
• Deu FL. How Patient Do Chinese Patients Need to Be. McKinsey & Company Greater China Published on March 31, 2016 Available from: https://www.linkedin.com/pulse/how-patient-do-chinese-patients-need-franck-le-deu Accessed September 27, 2019..
   Google Scholar
• Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. The Lancet. 2010;376(9747):1186–1193. doi:10.1016/S0140-6736(10)61152-X
   PubMed Web of Science ®Google Scholar
• Sumner A Where will the world’s poor live. CGD Working Paper 305. Washington, D.C.: Center for Global Development Available from: http://www.cgdev.org/content/publications/detail/1426481 Accessed October 8, 2019.
   Google Scholar
• Drabu S, Khatri S, Singh S, et al. Drugs and money – prices, affordability and cost containment. Int J Pharm Healthc Mark. 2011;5(1):67–69. doi:10.1108/17506121111121596
   Google Scholar
• China Daily USA. China Society. Cancer patients look to India for lifesaving drugs. 2015 1 28 Available from: http://usa.chinadaily.com.cn/china/2015-01/28/content_19426279.htm Accessed 73, 2019.
   Google Scholar
• Deloitte. Fortune favors the bold unlocking access across China. Available from: https://www2.deloitte.com/content/dam/Deloitte/cn/Documents/life-sciences-health-care/deloitte-cn-lshc-chinalshcindustryreportsection4-en-081014.pdf Accessed 73, 2019.
   Google Scholar
• Downing NS, Aminawung JA, Shah ND, et al. Regulatory review of novel therapeutics — comparison of three regulatory agencies. N Engl J Med. 2012;366:2284–2293. doi:10.1056/NEJMsa120022322591257
   PubMed Web of Science ®Google Scholar
• Regulatory Affairs Professional Society, Pharma Asia. China proposes new FDA rules to speed up foreign drug approvals. 2017 3 20 Available from: https://www.fiercepharma.com/pharma-asia/china-officially-process-to-speed-up-foreign-drug-approval Accessed 73, 2019.
   Google Scholar
• Center for Drug Evaluation, National Medical Products Administration, About us. Development history. Available from: http://www.cde.org.cn/htmlPage.jsp?htmlPageId=4 (in Chinese) Accessed 107, 2019.
   Google Scholar
• Center for Drug Evaluation, National Medical Products Administration. Annual report of China drug review 2012. Available from: http://www.cde.org.cn/news.do?method=largeInfo&id=312956 (in Chinese) Accessed 73, 2019.
   Google Scholar
• Xu L, Gao H, Kaitin KI, et al. Reforming China’s drug regulatory system. Nat Rev Drug Discov. 2018;17:858–859. doi:10.1038/nrd.2018.15030262888
   PubMed Web of Science ®Google Scholar
• Ahmadiani S, Nikfar S. Challenges of access to medicine and the responsibility of pharmaceutical companies: a legal perspective. DARU. 2016;24:13. doi:10.1186/s40199-016-0151-z27141958
   PubMed Web of Science ®Google Scholar
• United States Government Accountability Office. Drug pricing: research on savings from generic drug use. Available from: https://www.gao.gov/assets/590/588064.pdf Accessed 73, 2019.
   Google Scholar
• Hill A, Simmons B, Gotham D, et al. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Eradication. 2016;2(1):28–31. PMID: 27482432. PMC4946692.
   Google Scholar
• Cole AL, Dusetzina SB. Generic price competition for specialty drugs: too little, too late? Health Aff. 2018;37(5):738–742. PMID: 29733710. doi:10.1377/hlthaff.2017.1684
   Web of Science ®Google Scholar
• Sun J, Zhao H, Ma L, et al. Affordability of expensive medicines with significant public health implications under the intellectual property right protection system. Chinese J Evidence Based Med. 2014;14(5):509–516. (in Chinese). doi:10.7507/1672-2531.20140088
   Google Scholar
• Ncayiyana D. Antiretroviral therapy cannot be South Africa’s first priority. CMAJ. 2001;164(13):1857–1858.11450284
   PubMed Web of Science ®Google Scholar
• Luo W, Sun L, Zhou J.Evaluation of pharmaceutical industry structure optimization in China. Chinese J New Drugs. 2016;25(14):1566–1571. (in Chinese).
   Google Scholar
• Meng X, Song Y. SWOT analysis of generics development in China. China Pharm. 2016;27(28):3889–3892. (in Chinese). doi:10.6039/j.issn.1001-0408.2016.28.01
   Google Scholar
• European Commission. Economics of industrial research and innovation. The 2015 EU Industrial R&D Investment Scoreboard. Available from: https://iri.jrc.ec.europa.eu/rd_monitoring. Accessed November 22, 2019.
   Google Scholar
• Sun Y, Sun LH.Empirical analysis on the effect of pharmaceutical scientific & technological investment from government on pharmaceutical R&D expenditure. China Pharm. 2011;22(9):771–774. (in Chinese).
   Google Scholar
• Yang Z, Yuan J, Yin M. Present status analysis on domestic medicine technological innovation products incubators. Soft Sci Health. 2016;30(6):48–50. (in Chinese). doi:10.3969/j.issn.1003-2800.2016.06.012
   Google Scholar
• Li ZJ, Ma Y, Liu Y, et al. Descriptive systematic review on collaborative innovation of health industry in China. Chin Health Serv Manage. 2017;34(6):477–480. (in Chinese).
   Google Scholar
• Wu L, Chen Y. Novel drug research and development ability in China: an international comparison and analysis. Chinese J Health Policy. 2017;10(08):23–28. (in Chinese). doi:10.3969/j.issn.1674-2982.2017.08.005
   Google Scholar
• Deloitte. Opportunity and influence for localized development pharmaceutical R&D trends in China. Available from: https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/articles/pharmaceutical-rd-trends-in-china.html Accessed 73, 2019.
   Google Scholar
• Diao Y, Qian J, Liu Y, et al. Government insurance coverage and use and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. The Lancet. 2018;392(Supplement 1):S37. doi:10.1016/S0140-6736(18)32666-7
   Google Scholar
• Lucas C. Dying to survive and cancer care in China. Lancet Oncol. 2019;20(1):30. doi:10.1016/S1470-2045(18)30921-530614464
   PubMed Web of Science ®Google Scholar
• Perehudoff K, Toebes B, Hogerzeil H. A human rights-based approach to the reimbursement of expensive medicines. Bull World Health Organ. 2016;94(12):935–936. doi:10.2471/BLT.15.16637127994287
   PubMed Web of Science ®Google Scholar
• Science and Technology Daily News. How to address procurement barrier of novel medicines after evaluation process has been speed up? 2018 10 17 Available from: http://www.medsci.cn/article/show_article.do?id=1b40151303a1 (in Chinese) Accessed 73, 2019.
   Google Scholar
• People’s Daily. Why hospital buck passing patients? 2012 12 06 Available from: http://cpc.people.com.cn/pinglun/n/2012/1206/c78779-19809787.html. (in Chinese). Accessed November 22, 2019
   Google Scholar
• National Health Commission. Policy interpretation of the 2018 national essential medicines list. 2018 10 25 Available from: http://www.nhc.gov.cn/yaozs/s3582/201810/de12303b26a046e49d725f375fb31315.shtml (in Chinese) Accessed 107, 2019
   Google Scholar
• Sun J, Jiang F, Zhao Q, et al. The successful experiences of a developing country in achieving universal access to expensive life-saving medicines and it implications to China. China Pharm. 2017;28(3):289–294. (in Chinese). doi:10.6039/j.issn.1001-0408.2017.03.01
   Google Scholar
• Fonseca EM, Shadlen K, Bastos F. Brazil’s fight against hepatitis C — universalism, local production, and patents. N Engl J Med. 2019;380:605–607. doi:10.1056/NEJMp181295930763192
   PubMed Web of Science ®Google Scholar
• Jiang Y, Bi K. A view on compare of international new drugs innovation system with enlightenments to China. Sci Manage S.& T. 2010;31(2):40–45. (in Chinese). doi:10.1016/S1570-6672(09)60061-1
   Google Scholar
• Center for Drug Evaluation. National Medical Products Administration. Annual Report of China Drug Review 2018 Available from: http://www.nmpa.gov.cn/WS04/CL2196/338621.html (in Chinese) Accessed 73, 2019.
   Google Scholar
• Shao R, Zhao D, Jiang R.Policies and trends of innovative drug research and development in China. China Food Drug Adm Magazine. 2018;16(01):15–19. (in Chinese).
   Google Scholar
• United Nations Development Programme Asia-Pacific regional centre. Intellectual Property Rights and Access to Affordable ARVs in China. Bangkok: UNDP; 2013.
   Google Scholar
• Chee YL, Chen X. Intellectual property right and accessibility of inexpensive medicines: lessons from Asian countries. Pat Law Res. 2007.
   Google Scholar
• Kaplana WA, Ritzb LS, Vitelloc M, et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012;106(3):211−24.22694970
   PubMed Web of Science ®Google Scholar
• Khor M Compulsory license and “Government Use” to promote access to medicines: some examples. Third World Network: Malaysia; 2014 Available from: http://www.twn.my/title2/books/CompulsoryLicense.htm Accessed 73, 2019.
   Google Scholar
• Department of Pharmaceuticals of India. Pharmaceutical Policy 2002. 2002 2 15 Available from: http://pharmaceuticals.gov.in/policy/pharmaceutical-policy-2002 Accessed 73, 2019.
   Google Scholar
• Ministry of Finance. Notice on VAT policy of anti-cancer drugs. Documents No. 47 of 2018. Available from: http://www.chinatax.gov.cn/n810341/n810755/c3421680/content.html (in Chinese) Accessed 73, 2019.
   Google Scholar
• Statista. Health & Pharmaceuticals. Pharmaceutical Products & Market. VAT rate on prescription-only drugs in Europe 2018. Available from: https://www.statista.com/statistics/458957/vat-rate-on-prescription-only-drugs-in-europe/ (in Chinese) Accessed 73, 2019.
   Google Scholar
• State Taxation Administration. VAT policy for rare disease drugs. Document No. 24 of 2019. Available from: http://www.chinatax.gov.cn/n810341/n810755/c4082485/content.html (in Chinese) Accessed 73, 2019.
   Google Scholar
• Sang G. Progress of the 2018 national major new medicines developments project and forecast of the 13th five-year plan. China Biotechnol. 2019;39(2):3–12. (in Chinese). doi:10.13523/j.cb.20190202
   Google Scholar
• Chai H, Liu Z, Wang Z. Preliminary analysis on the establishment of drug innovation system and the innovation progress of Chinese pharmaceutical enterprises. West China Med J. 2018;33(03):359–363. in Chinese. doi:10.7507/1002-0179.201801164
   Google Scholar
• National Bureau of Statistics of China. public spending on pharmaceutical R&D. Available from: http://data.stats.gov.cn (in Chinese) Accessed 73, 2019.
   Google Scholar
• Congressional Budget Office of the United States. Estimating the long-term effects of federal R&D spending: CBO’s current approach and research needs. 2018 6 21 Available from: https://www.cbo.gov/publication/54089 Accessed 73, 2019.
   Google Scholar
• Chu Y, Ma A. R&D expenditure analysis of Chinese pharmaceutical companies. Mod Bus Trade Ind. 2013; 2: 3–5. Available from: https://www.china-briefing.com/news/chinas-commercial-healthcare-insurance-industry-on-the-fast-track/ (in Chinese) Accessed July 31, 2019
   Google Scholar
• National Health Commission. The announcement of the results of medicines price national negotiation. Document No. 515 of 2016. 2016 5 20 Available from: http://www.nhc.gov.cn/yaozs/s7655/201605/58c5bc1ed0f14c75b8f15f1c149b35f4.shtml (in Chinese) Accessed 108, 2019.
   Google Scholar
• Ministry of Human Resources and Social Security. The announcement of inclusion of 36 national price negotiation medicines into the basic health insurance medicines reimbursement list. Document No. 54 of 2017. 2017 7 13 Available from: http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/201707/t20170718_274153.html (in Chinese) Accessed 108, 2019.
   Google Scholar
• National Healthcare Security Administration. Notice on the inclusion of 17 anti-cancer medicines into the national basic health insurance medicines reimbursement list. Document No.17 of 2018. 2018 10 10 Available from: http://www.nhsa.gov.cn/art/2018/10/10/art_37_1057.html (in Chinese) Accessed 108, 2019.
   Google Scholar
• Li C, Cui D, Peng H, et al. Practical study of brining negotiation medicines into health insurance management. Chinese J Hosp Manage. 2018;38(5):39–41. (in Chinese).
   Google Scholar
• National Healthcare Security Administration. Workplan for the adjustment of the national basic health insurance medicines reimbursement list 2019 Available from: http://www.nhsa.gov.cn/art/2019/4/17/art_37_1214.html (in Chinese) Accessed 930, 2019.
   Google Scholar
• China National Health and Development and research center of the national health commission of P.R. China. China health account report. Beijing: CNHDRC;2018 (in Chinese).
   Google Scholar
• Dezan Shira & Associates. China Briefing. China’s Commercial Healthcare Insurance Industry on the fast-track. 2015 12 24 Available from: https://www.china-briefing.com/news/chinas-commercial-healthcare-insurance-industry-on-the-fast-track/ Accessed 731, 2019.
   Google Scholar
• Sekhri N, Savedoff W. Private health insurance: implications for developing countries. Bull World Health Organ. 2005;83(2):127–138. doi:10.1590/S0042-9686200500020001315744405
   PubMed Web of Science ®Google Scholar
• General Office of the State Council of the People's Republic of China. Strengthening the Performance Appraisal of Third-level Public Hospitals. (2019) 4. http://www.gov.cn/zhengce/content/2019-01/30/content_5362266.htm. (in Chinese) Accessed November 22, 2019.
   Google Scholar
• People’s Daily. Prices of selected drugs in 11 pilot cities dropped by 52% on average. Available from: http://www.gov.cn/zhengce/2019-01/18/content_5358881.htm (in Chinese) Accessed 73, 2019.
   Google Scholar